The Experts below are selected from a list of 327 Experts worldwide ranked by ideXlab platform
David A Katzka - One of the best experts on this subject based on the ideXlab platform.
-
variations in the clinical course of patients with herpes simplex virus esophagitis based on immunocompetence and presence of underlying Esophageal Disease
Digestive Diseases and Sciences, 2019Co-Authors: Patrick Hoversten, Amrit K Kamboj, Tsung Teh Wu, David A KatzkaAbstract:Background and aims Herpes simplex esophagitis (HSE) is the second most common cause of infectious esophagitis and occurs in both immunocompetent and immunocompromised patients. The aim of this study was to reappraise the clinical course of HSE in different patient populations based on degree of immunocompetence and the presence or absence of underlying Esophageal Disease. Methods Patients with histopathologically confirmed HSE identified from the Mayo Clinic pathology database from 2006 to 2016 were included in this study. Relevant demographic, clinical, and endoscopic data were retrospectively reviewed and compared between two cohorts: (a) immunocompromised and immunocompetent patients and (b) patients with and without underlying Esophageal disorders. Results Forty-six patients were included in the study. The most common presenting symptoms were odynophagia (34.8%) and dysphagia (30.4%). Thirty-three (71.7%) patients were immunocompromised, and these patients who experienced longer duration of symptoms (25.5 ± 23.4 days vs. 7.0 ± 5.5 days, p = 0.04) were more likely to require an extension of treatment course (38.1% vs. 8.3%, p = 0.05) compared to their immunocompetent counterparts. Seventeen (37%) patients had underlying Esophageal Disease, and these patients were more likely to have concomitant Esophageal candidiasis (41.2% vs. 10.3%, respectively; p = 0.01). Conclusion Herpes simplex virus causes esophagitis in both immunocompetent and immunocompromised patients. While the Disease course appears to be self-limited for all patient populations, clinical and endoscopic differences in the Disease presentation and clinical course based on immune status and the presence or absence of underlying Esophageal Disease exist.
-
variations in the clinical course of patients with herpes simplex virus esophagitis based on immunocompetence and presence of underlying Esophageal Disease
Digestive Diseases and Sciences, 2019Co-Authors: Patrick Hoversten, Amrit K Kamboj, David A KatzkaAbstract:Herpes simplex esophagitis (HSE) is the second most common cause of infectious esophagitis and occurs in both immunocompetent and immunocompromised patients. The aim of this study was to reappraise the clinical course of HSE in different patient populations based on degree of immunocompetence and the presence or absence of underlying Esophageal Disease. Patients with histopathologically confirmed HSE identified from the Mayo Clinic pathology database from 2006 to 2016 were included in this study. Relevant demographic, clinical, and endoscopic data were retrospectively reviewed and compared between two cohorts: (a) immunocompromised and immunocompetent patients and (b) patients with and without underlying Esophageal disorders. Forty-six patients were included in the study. The most common presenting symptoms were odynophagia (34.8%) and dysphagia (30.4%). Thirty-three (71.7%) patients were immunocompromised, and these patients who experienced longer duration of symptoms (25.5 ± 23.4 days vs. 7.0 ± 5.5 days, p = 0.04) were more likely to require an extension of treatment course (38.1% vs. 8.3%, p = 0.05) compared to their immunocompetent counterparts. Seventeen (37%) patients had underlying Esophageal Disease, and these patients were more likely to have concomitant Esophageal candidiasis (41.2% vs. 10.3%, respectively; p = 0.01). Herpes simplex virus causes esophagitis in both immunocompetent and immunocompromised patients. While the Disease course appears to be self-limited for all patient populations, clinical and endoscopic differences in the Disease presentation and clinical course based on immune status and the presence or absence of underlying Esophageal Disease exist.
Patrick Hoversten - One of the best experts on this subject based on the ideXlab platform.
-
variations in the clinical course of patients with herpes simplex virus esophagitis based on immunocompetence and presence of underlying Esophageal Disease
Digestive Diseases and Sciences, 2019Co-Authors: Patrick Hoversten, Amrit K Kamboj, Tsung Teh Wu, David A KatzkaAbstract:Background and aims Herpes simplex esophagitis (HSE) is the second most common cause of infectious esophagitis and occurs in both immunocompetent and immunocompromised patients. The aim of this study was to reappraise the clinical course of HSE in different patient populations based on degree of immunocompetence and the presence or absence of underlying Esophageal Disease. Methods Patients with histopathologically confirmed HSE identified from the Mayo Clinic pathology database from 2006 to 2016 were included in this study. Relevant demographic, clinical, and endoscopic data were retrospectively reviewed and compared between two cohorts: (a) immunocompromised and immunocompetent patients and (b) patients with and without underlying Esophageal disorders. Results Forty-six patients were included in the study. The most common presenting symptoms were odynophagia (34.8%) and dysphagia (30.4%). Thirty-three (71.7%) patients were immunocompromised, and these patients who experienced longer duration of symptoms (25.5 ± 23.4 days vs. 7.0 ± 5.5 days, p = 0.04) were more likely to require an extension of treatment course (38.1% vs. 8.3%, p = 0.05) compared to their immunocompetent counterparts. Seventeen (37%) patients had underlying Esophageal Disease, and these patients were more likely to have concomitant Esophageal candidiasis (41.2% vs. 10.3%, respectively; p = 0.01). Conclusion Herpes simplex virus causes esophagitis in both immunocompetent and immunocompromised patients. While the Disease course appears to be self-limited for all patient populations, clinical and endoscopic differences in the Disease presentation and clinical course based on immune status and the presence or absence of underlying Esophageal Disease exist.
-
variations in the clinical course of patients with herpes simplex virus esophagitis based on immunocompetence and presence of underlying Esophageal Disease
Digestive Diseases and Sciences, 2019Co-Authors: Patrick Hoversten, Amrit K Kamboj, David A KatzkaAbstract:Herpes simplex esophagitis (HSE) is the second most common cause of infectious esophagitis and occurs in both immunocompetent and immunocompromised patients. The aim of this study was to reappraise the clinical course of HSE in different patient populations based on degree of immunocompetence and the presence or absence of underlying Esophageal Disease. Patients with histopathologically confirmed HSE identified from the Mayo Clinic pathology database from 2006 to 2016 were included in this study. Relevant demographic, clinical, and endoscopic data were retrospectively reviewed and compared between two cohorts: (a) immunocompromised and immunocompetent patients and (b) patients with and without underlying Esophageal disorders. Forty-six patients were included in the study. The most common presenting symptoms were odynophagia (34.8%) and dysphagia (30.4%). Thirty-three (71.7%) patients were immunocompromised, and these patients who experienced longer duration of symptoms (25.5 ± 23.4 days vs. 7.0 ± 5.5 days, p = 0.04) were more likely to require an extension of treatment course (38.1% vs. 8.3%, p = 0.05) compared to their immunocompetent counterparts. Seventeen (37%) patients had underlying Esophageal Disease, and these patients were more likely to have concomitant Esophageal candidiasis (41.2% vs. 10.3%, respectively; p = 0.01). Herpes simplex virus causes esophagitis in both immunocompetent and immunocompromised patients. While the Disease course appears to be self-limited for all patient populations, clinical and endoscopic differences in the Disease presentation and clinical course based on immune status and the presence or absence of underlying Esophageal Disease exist.
Amrit K Kamboj - One of the best experts on this subject based on the ideXlab platform.
-
variations in the clinical course of patients with herpes simplex virus esophagitis based on immunocompetence and presence of underlying Esophageal Disease
Digestive Diseases and Sciences, 2019Co-Authors: Patrick Hoversten, Amrit K Kamboj, Tsung Teh Wu, David A KatzkaAbstract:Background and aims Herpes simplex esophagitis (HSE) is the second most common cause of infectious esophagitis and occurs in both immunocompetent and immunocompromised patients. The aim of this study was to reappraise the clinical course of HSE in different patient populations based on degree of immunocompetence and the presence or absence of underlying Esophageal Disease. Methods Patients with histopathologically confirmed HSE identified from the Mayo Clinic pathology database from 2006 to 2016 were included in this study. Relevant demographic, clinical, and endoscopic data were retrospectively reviewed and compared between two cohorts: (a) immunocompromised and immunocompetent patients and (b) patients with and without underlying Esophageal disorders. Results Forty-six patients were included in the study. The most common presenting symptoms were odynophagia (34.8%) and dysphagia (30.4%). Thirty-three (71.7%) patients were immunocompromised, and these patients who experienced longer duration of symptoms (25.5 ± 23.4 days vs. 7.0 ± 5.5 days, p = 0.04) were more likely to require an extension of treatment course (38.1% vs. 8.3%, p = 0.05) compared to their immunocompetent counterparts. Seventeen (37%) patients had underlying Esophageal Disease, and these patients were more likely to have concomitant Esophageal candidiasis (41.2% vs. 10.3%, respectively; p = 0.01). Conclusion Herpes simplex virus causes esophagitis in both immunocompetent and immunocompromised patients. While the Disease course appears to be self-limited for all patient populations, clinical and endoscopic differences in the Disease presentation and clinical course based on immune status and the presence or absence of underlying Esophageal Disease exist.
-
variations in the clinical course of patients with herpes simplex virus esophagitis based on immunocompetence and presence of underlying Esophageal Disease
Digestive Diseases and Sciences, 2019Co-Authors: Patrick Hoversten, Amrit K Kamboj, David A KatzkaAbstract:Herpes simplex esophagitis (HSE) is the second most common cause of infectious esophagitis and occurs in both immunocompetent and immunocompromised patients. The aim of this study was to reappraise the clinical course of HSE in different patient populations based on degree of immunocompetence and the presence or absence of underlying Esophageal Disease. Patients with histopathologically confirmed HSE identified from the Mayo Clinic pathology database from 2006 to 2016 were included in this study. Relevant demographic, clinical, and endoscopic data were retrospectively reviewed and compared between two cohorts: (a) immunocompromised and immunocompetent patients and (b) patients with and without underlying Esophageal disorders. Forty-six patients were included in the study. The most common presenting symptoms were odynophagia (34.8%) and dysphagia (30.4%). Thirty-three (71.7%) patients were immunocompromised, and these patients who experienced longer duration of symptoms (25.5 ± 23.4 days vs. 7.0 ± 5.5 days, p = 0.04) were more likely to require an extension of treatment course (38.1% vs. 8.3%, p = 0.05) compared to their immunocompetent counterparts. Seventeen (37%) patients had underlying Esophageal Disease, and these patients were more likely to have concomitant Esophageal candidiasis (41.2% vs. 10.3%, respectively; p = 0.01). Herpes simplex virus causes esophagitis in both immunocompetent and immunocompromised patients. While the Disease course appears to be self-limited for all patient populations, clinical and endoscopic differences in the Disease presentation and clinical course based on immune status and the presence or absence of underlying Esophageal Disease exist.
Ryan Law - One of the best experts on this subject based on the ideXlab platform.
-
Valuing innovative endoscopic techniques: endoscopic suturing to prevent stent migration for benign Esophageal Disease.
Gastrointestinal endoscopy, 2019Co-Authors: Eric D. Shah, Amy E. Hosmer, Arpan Patel, Shannon Morales, Ryan LawAbstract:Background and Aims Reimbursement often presents a significant barrier to widespread adoption of innovative endoscopic devices. We aimed to determine the value (defined as cost savings to a payer) of endoscopic suturing devices in preventing the migration of Esophageal stents placed for benign Esophageal Diseases. Methods A decision-analytic model was constructed from a payer perspective evaluating fully covered metal stent placement for benign Esophageal Diseases (fistula, leak, perforation, or stricture) in a hospital outpatient setting. The model compared 2 strategies: endoscopic suturing to anchor the stent or no suture. Health care outcomes and costs were derived from published systematic reviews and national databases (U.S. Food and Drug Administration Manufacturer and User Facility Device Experience [MAUDE] for safety data; 2018 Medicare Physician Fee Schedule and Provider Utilization and Payment Data databases for reimbursement data). Results From a payer perspective, reimbursement for care increased by US$1487.98 without endoscopic suturing per patient, compared with US$621.06 with endoscopic suturing, to cover the risk of stent migration in addition to usual professional and facility reimbursement for stent placement. Thus, an average cost saving of US$866.92 per patient was achieved with endoscopic suturing to reduce stent migration risks. Cost savings associated with suturing ranged from US$147.48 to US$1586.36 per patient, based on the indication for the procedure in sensitivity analysis. Cost savings increased with higher rates of technical success in suture placement. Conclusions Creating a defined reimbursement pathway for endoscopic suture fixation of a stent for the treatment of benign Esophageal Diseases appears to be justified from a payer perspective.
Tsung Teh Wu - One of the best experts on this subject based on the ideXlab platform.
-
variations in the clinical course of patients with herpes simplex virus esophagitis based on immunocompetence and presence of underlying Esophageal Disease
Digestive Diseases and Sciences, 2019Co-Authors: Patrick Hoversten, Amrit K Kamboj, Tsung Teh Wu, David A KatzkaAbstract:Background and aims Herpes simplex esophagitis (HSE) is the second most common cause of infectious esophagitis and occurs in both immunocompetent and immunocompromised patients. The aim of this study was to reappraise the clinical course of HSE in different patient populations based on degree of immunocompetence and the presence or absence of underlying Esophageal Disease. Methods Patients with histopathologically confirmed HSE identified from the Mayo Clinic pathology database from 2006 to 2016 were included in this study. Relevant demographic, clinical, and endoscopic data were retrospectively reviewed and compared between two cohorts: (a) immunocompromised and immunocompetent patients and (b) patients with and without underlying Esophageal disorders. Results Forty-six patients were included in the study. The most common presenting symptoms were odynophagia (34.8%) and dysphagia (30.4%). Thirty-three (71.7%) patients were immunocompromised, and these patients who experienced longer duration of symptoms (25.5 ± 23.4 days vs. 7.0 ± 5.5 days, p = 0.04) were more likely to require an extension of treatment course (38.1% vs. 8.3%, p = 0.05) compared to their immunocompetent counterparts. Seventeen (37%) patients had underlying Esophageal Disease, and these patients were more likely to have concomitant Esophageal candidiasis (41.2% vs. 10.3%, respectively; p = 0.01). Conclusion Herpes simplex virus causes esophagitis in both immunocompetent and immunocompromised patients. While the Disease course appears to be self-limited for all patient populations, clinical and endoscopic differences in the Disease presentation and clinical course based on immune status and the presence or absence of underlying Esophageal Disease exist.